Post-Heart Transplantation Survival Comes with a Heavy Cardiovascular-Kidney-Metabolic Burden: New Data on DM2 and CKD Risks
Posted inCardiology Nephrology news Transplantation

Post-Heart Transplantation Survival Comes with a Heavy Cardiovascular-Kidney-Metabolic Burden: New Data on DM2 and CKD Risks

A longitudinal study of 944 heart transplant recipients reveals a staggering incidence of metabolic and renal dysfunction. While diabetes significantly increases mortality risk, the study highlights the potential of SGLT2 inhibitors and GLP1RAs to mitigate these chronic complications in the post-transplant population.
Optimizing Acid-Base Stability in CVVH: Why Lower Bicarbonate Fluids Outperform Standard Concentrations During Regional Citrate Anticoagulation
Posted inCritical Care Nephrology news

Optimizing Acid-Base Stability in CVVH: Why Lower Bicarbonate Fluids Outperform Standard Concentrations During Regional Citrate Anticoagulation

This randomized controlled trial demonstrates that a lower bicarbonate replacement fluid (22 mmol/l) provides superior acid-base stability compared to a higher concentration (30 mmol/l) during CVVH with citrate anticoagulation, significantly reducing metabolic excursions without delaying acidosis correction.
Conservative Kidney Management Versus Dialysis in Older Adults with Kidney Failure: Evidence Is Inconclusive — What Clinicians Should Know
Posted inNephrology news

Conservative Kidney Management Versus Dialysis in Older Adults with Kidney Failure: Evidence Is Inconclusive — What Clinicians Should Know

A 2025 Cochrane review of 24 non-randomised studies (26,127 participants) found very low‑certainty evidence comparing conservative kidney management (CKM) with dialysis in people aged ≥65 with stage 5 chronic kidney disease; survival and quality-of-life differences are uncertain, highlighting the need for individualized decisions and higher-quality research.
Comprehensive Review of the EMPEROR-Preserved Trial: Efficacy and Outcomes of Empagliflozin in Heart Failure with Preserved Ejection Fraction
Posted inCardiology Clinical Updates Diabetes & Endocrinology Nephrology news

Comprehensive Review of the EMPEROR-Preserved Trial: Efficacy and Outcomes of Empagliflozin in Heart Failure with Preserved Ejection Fraction

This review comprehensively summarizes recent studies (2021–2024) from the EMPEROR-Preserved trial, highlighting empagliflozin’s consistent benefits on cardiovascular and renal outcomes, quality of life, and key clinical subgroups in HFpEF patients.
Unequal and Multisystem Mortality Risks After Tropical Cyclones: Renal, Injury, Infectious and Chronic Disease Burdens Across Nine Countries
Posted inNephrology news Public Health

Unequal and Multisystem Mortality Risks After Tropical Cyclones: Renal, Injury, Infectious and Chronic Disease Burdens Across Nine Countries

A multinational time-series study across nine countries found increased short-term mortality after tropical cyclones for multiple causes — highest for renal disease and injuries — with larger effects in deprived and cyclone-naïve communities and stronger associations with cyclone-related rainfall.